GAT100 is a negative allosteric modulator and covalent allosteric probe for cannabinoid receptor type 1 (CB1R). GAT100 acts as a positive allosteric modulator for orthosteric agonist CP55,940 binding to regulate the CB1R signaling pathway. GAT100 reduces the potency and efficacy of orthosteric CB1R agonists in terms of β-arrestin 1 recruitment, phosphorylation of PLCβ3 and ERK1/2, cAMP accumulation, and CB1R internalization. GAT100 is applicable to the research of psychobehavioral and somatic diseases.

Ganglioside GT1b (porcine) ammonium is a member of the ganglioside family. Ganglioside GT1b (porcine) ammonium acts as a protective signal against nerve injury-induced spinal synapse elimination. Ganglioside GT1b (porcine) ammonium induces HA synthesis and the phosphorylation of Akt/mTOR in orbital fibroblasts. Ganglioside GT1b (porcine) ammonium enhances porcine oocyte maturation and induces activation of EGFR and ERK1/2 signaling. Ganglioside GT1b (porcine) ammonium is a putative host cell receptor for the Merkel cell polyomavirus. Ganglioside GT1b (porcine) ammonium can be used for the researches of cancer, infection, immunology, endocrinology and neurological disease, such as Thyroid eye disease.

Ganglioside GQ1b (porcine brain) (tetraammonium) is a glycosphingolipid.

Ganglioside GD1b (porcine brain) (diammonium) is a glycosphingolipid.

Galloyl-coenzyme A thioester is a CoA-thioester of Gallic acid that can be found in plants as an intermediate in gallotannin biosynthesis.Galloyl-coenzyme A thioester possesses spectral properties that support photometric assay use in enzymatic studies.

Gallamine is an allosteric, selective muscarinic M2 acetylcholine receptor antagonist (EC50: 130 nM for [3H]NMS dissociation from porcine muscarinic M2 receptors). Gallamine is also an acetylcholinesterase inhibitor (IC50s : 1070 μM, 1480 μM, 235  μM for EeAChE, hAChE, hBChE, respectively (in the absence of MeCN)). Gallamine increases free norepinephrine levels. Gallamine can be used as a muscle relaxant.

Gal-GIcNAc-oxazoline (compound 24) is an N-acetylglucosamine (GlcNAc) and azide-modified disaccharide that can be used to label antibodies. Gal-GIcNAc-oxazoline can be synthesized as an ADC via click chemistry.

GABRA5 modulator-1 is a GABRA5 modulator.

G9a-IN-4 is a G9a inhibitor with high selectivity (IC50 = 32 nM). G9a-IN-4 shows high selectivity against the other tested lysine/arginine methyltransferases. G9a-IN-4 exhibits high enzymatic activity against G9a and more potent antiproliferative effects against all tested cancer cells. G9a-IN-4 significantly suppresses the H3K9me2 level. G9a-IN-4 triggers autophagy by inducing the production of ROS, thus leading to cell apoptosis and cell cycle arrest at G0/G1 in CT26 colon cells. G9a-IN-4 can be used for the study of colon cancer.

G6PD-IN-2 is a Plasmodium falciparum glucose-6-phosphate dehydrogenase (G6PD) inhibitor with an IC50 value of 0.2 μM. G6PD-IN-2 exerts weak inhibitory activity on Plasmodium falciparum glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase (PfGluPho) with an IC50 value of 22.0 μM. G6PD-IN-2 inhibits growth of Plasmodium falciparum 3D7 strain and exhibits low cytotoxicity in hepatocytes. G6PD-IN-2 can be used for the research of malaria.

FXR DUBTAC IN-1 (compound D11) is a deubiquitinase-targeting chimeric molecule (DUBTAC) that targets FXR, with a Ka value of 2.12e-5 M for FXR. FXR DUBTAC IN-1 recruits the deubiquitinase OTUB1, binds to OTUB1 and forms a ternary complex with FXR, reduces the polyubiquitination level of FXR, prevents FXR degradation via the ubiquitin-proteasome pathway, and elevates the protein level of FXR. FXR DUBTAC IN-1 can be used in the research of cholestatic liver injury.

FXR agonist 17 is an orally active, steroidal FXR agonist with EC50 values of 42.2 nM (TR-FRET) and 176.4 nM (luciferase reporter assay), respectively. FXR agonist 17 activates TGR5 (EC50 = 2.6 μM) but does not activate hMRGPRX4. FXR agonist 17 exerts anti-inflammatory, hepatoprotective and antifibrotic effects, improves the non-alcoholic steatohepatitis (NAFLD) activity score and reduces the severity of liver fibrosis. FXR agonist 17 can be used for the research of NAFLD, cholestatic liver disease and liver fibrosis.

FXR agonist 16 is a FXR agonist with an EC50 of 2.2 μM. FXR agonist 16 activates FXR transcriptional activity, upregulates SHP and BSEP, and downregulates Cyp7a1. FXR agonist 16 exhibits hepatoprotective activity and reduces AST and ALT levels in free fatty acid-induced hepatocellular injury models. FXR agonist 16 can be used for the research of liver injury.

FXR agonist 15 is a selective, potent and orally active farnesoid X receptor (FXR) agonist with EC50 of 0.76 μM. FXR agonist 15 exhibits no obvious activation on other nuclear receptors including LXRα/β, PXR, PPARα/β/γ, THR-β, with EC50 values all >10 μM. FXR agonist 15 can alleviate steatosis, lobular inflammation, hepatocyte ballooning and liver fibrosis. FXR agonist 15 can be used for the research of nonalcoholic steatohepatitis (NASH).

Fusidic acid prodrug is an antibacterial agent. Fusidic acid prodrug has significant antibacterial activity against Pseudomonas aeruginosa (MIC = 4 µg/mL). Fusidic acid prodrug can be used in the research of infectious conditions.

Fumarranol, a Fumagillin analogue, is a selective type 2 methionine aminopeptidase (MetAP2) inhibitor with a human IC50 of 3.2 μM. Fumarranol inhibits proliferation of bovine aortic endothelial cells and inhibits angiogenesis in a mouse matrigel plug model. Fumarranol can be used for the researches of cancer, diabetic retinopathy, age-related macular degeneration.

FtsZ-IN-14 (example XI) is a filamentous temperature-sensitive protein Z (FtsZ) inhibitor. FtsZ-IN-14 can inhibit the growth of various drug-resistant bacteria in vitro and can be used to prepare antibiotics against drug-resistant bacteria.

FTC-146 precursor (Compound s6) is a drug intermediate that can be used to prepare σ-1 receptor positron emission tomography tracers ([¹⁸F]FTC-146).

Frenlosirsen sodium is an antisense oligonucleotide targeted to IRF4. It is used for study of relapsed/refractory multiple myeloma (RRMM).

FPL 66564 is a short-acting angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 5.7 nM against rabbit ACE. FPL 66564 inhibits ACE activity at the functional level and is hydrolyzed in human blood into inactive hydrophilic metabolites. FPL 66564 modulates angiotensin I-induced pressor responses in anesthetized rats, and its effects rapidly return to baseline after cessation of intravenous infusion. FPL 66564 can be used for research on cardiovascular regulation related to critical illness.

Formylphosphonic acid is a nucleoside metabolite.

Fonsartan (HR720) is an AT1 receptor antagonist. Fonsartan can be used for the study of myocardial infarction (MI).

Fmoc-NH-C2-diphosphate-dexamethasone (Compound 17) is a derivative of Dexamethasone and can be used as a drug intermediate for the synthesis of the Raltitrexed-Dexamethasone conjugate.

Fmoc-Lys[Octa(OtBu)-Glu-OtBu]-OH is an Fmoc-protected amino acid derivative.

Fmoc-Gly-Gly-Phe-Gly-Paclitaxel (Compound 16a-3) is a drug-linker conjugates for ADC. Fmoc-Gly-Gly-Phe-Gly-Paclitaxel contains the ADC linker Fmoc-Gly-Gly-Phe-OH and a potent tubulin polymerization inhibitor Paclitaxel. Fmoc-Gly-Gly-Phe-Gly-Paclitaxel can be used for the research of cancer.

Fmoc-Gly-Gly-Phe-Gly-Docetaxel (compound 16h-3) is a drug-linker conjugate for ADC, which comprises a microtubule depolymerization inhibitor and a linker. Puxitatug samrotecan drug-linker can be used to synthesize antibody-drug conjugate (ADC).

Fmoc-C-PEG3-C3-Succinamic acid is a PROTAC linker that can be used in the synthesis of PROTACs.

Fmoc-Asp(OtBu)-OH-15N is the 15N-labeled Fmoc-Asp(OtBu)-OH. Fmoc-Asp(OtBu)-OH (4-tert-Butyl N-(fluoren-9-ylmethoxycarbonyl)-L-aspartate) is an aspartate derivative containing amine protecting group Fmoc. Fmoc-Asp(OtBu)-OH can be used for peptide synthesis.

Fmoc-Asp(OMpe)-Cbz is a drug intermediate that can be used for the synthesis of Fmoc-Asp(OMpe)-OH.

Fluorofelbamate, a Felbamate analog, is a potent NMDA receptor antagonist. Fluorofelbamate exhibits anticonvulsant and antiepileptogenic effects in an experimental rat model of self-sustaining status epilepticus (SSSE). Fluorofelbamate can be used for epilepsy research.